🔗 Share this article

While America undertakes historic revisions to its vaccine recommendations, a particular individual has emerged somewhat surprisingly: Høeg, a Danish American sports medicine doctor and epidemiologist who first made her name by questioning COVID-19 vaccines throughout the pandemic and has zeroed in on potential deaths following Covid immunization in her brief position at the FDA.

Planned Shifts to Childhood Vaccine Program

Health officials had intended to announce major changes to the pediatric vaccination calendar earlier this month, aligning the US with the Danish national calendar, it is understood – a major change that would put the US at odds with a large portion of the world with insufficient data for improved outcomes. The planned update has been delayed until the coming year.

Rather than the director of the vaccine center, Høeg is listed to present at the gathering. She was just designated acting director of the FDA’s CDER, the fifth person to head the division this year.

Consolidating Power at the FDA

The acting appointment might represent a strengthened alliance between the drug and vaccine branches as Dr. Høeg and Dr. Prasad consolidate power at the FDA – and it suggests a renewed priority upon rolling back already-approved immunizations at the FDA.

The new acting director has often pushed for halting certain pediatric vaccine recommendations in the US so as to align more in line with Denmark's approach, a nation with nationalized medicine and a number of inhabitants roughly the population of Wisconsin’s.

So far statements, she has kept her attention on immunizations – usually the domain of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to pharmaceutical oversight.

Questions Over Background

The appointee has no obvious background in drug development, regulation or leadership, which has been typical for previous directors of the CBER. She has been employed at the FDA as a top consultant to the agency head and the vaccine center since earlier this year.

“It seems she lacks to have any of the qualifications” for overseeing the CDER, remarked Jonathan Howard. “She’s never run a scientific study. She lacks experience in running a major agency. She has no expertise in industry regulation.”

Previous commissioners of CBER would “grasp laws and regulations and the research of medication creation”, noted Dr. Janet Woodcock. “Frankly, she has not acquired the sort of resume that prior appointees who ran CBER have had.”

CDER has an immense range of responsibilities at the FDA, the former commissioner emphasized.

“The public just pays attention on the new drug program, but the generic drug division authorizes thousands of generic medications. There is also a biosimilars division, over-the-counter program and more, and all of those need to be looked after,” she explained. “The area you neglect, that is precisely what that I always told people is going to cause problems.”

Additionally, a substantial administrative component to the role, which supervises over 5,000 staff members. “It is a huge leadership role, if you execute it properly,” the former official concluded.

Response and Contentious Policies

When asked about inquiries about Høeg’s credentials and whether this appointment signifies more teamwork among agency officials on immunizations, a representative responded that the “questions rely on incorrect presumptions”.

“Her experience matches the functions of her position,” the representative explained, pointing to the time Høeg spent guiding the agency head on “pharmaceutical safety and approval science, including computerized risk analysis and immunization monitoring”.

As acting director, Dr. Høeg takes over the commissioner’s new expedited review system, a controversial one-day drug-approval program that reportedly worried her former heads. “How are these therapies being selected for this voucher program? Who takes the calls?” Howard asked. “There is a lot of confidentiality happening at the agency right now.”

Broadly speaking, he stated, “the agency looks to be trending towards more relaxed regulations of most medications, with the exception of vaccines.”

Public Track Record on Vaccines

With immunizations, Dr. Høeg has a more documented, if concerning, past, critics observe. She released a research paper using unconfirmed crowd-sourced reports to assess the frequency of myocarditis following COVID-19 vaccination. She advised the Florida chief medical officer Joseph Ladapo, who reportedly have modified findings to indicate COVID-19 vaccinations are riskier than they are.

Among her “wish list” for the incoming government included revising regulations for recently developed shots and halting “non-essential” immunizations, she said after the election on a audio program. At the agency, Høeg has allegedly floated the idea of preventing young men from getting COVID-19 vaccines.

“She is an all-around dogmatist who commences with her conclusions and works backwards to retrofit the science in a highly deceptive, fraudulent manner,” Dr. Howard argued.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with fellow contrarians, {like|